PMID- 38063120
OWN - NLM
STAT- MEDLINE
DCOM- 20240105
LR  - 20240105
IS  - 1165-158X (Electronic)
IS  - 0145-5680 (Linking)
VI  - 69
IP  - 12
DP  - 2023 Nov 30
TI  - Effect of miR-146a polymorphism on lipoic acid therapy in patients with T2DM 
      peripheral polyneuropthy.
PG  - 38-43
LID - 10.14715/cmb/2023.69.12.7 [doi]
AB  - For investigating the impact of miR-146a rs2910164 polymorphism on the 
      therapeutic efficacy of lipoic acid therapy in patients with type 2 diabetes 
      mellitus (T2DM) peripheral neuropathy (DPN). 106 T2DM-DPN patients in our 
      hospital from Jan. 2020- 2022 were selected. The probe detection method was 
      utilized to determine the polymorphism of the miR-146a rs2910164 gene in 
      peripheral blood. All patients were treated with zinc sulfate for 3 weeks period. 
      According to the treatment effect, 37 patients who were ineffective in treatment 
      will be divided into an ineffective group, and 79 patients who were effective in 
      treatment will be divided into an effective group. The condition of miR-146a gene 
      peptides was analyzed after treatment in both groups. The motor nerve conduction 
      velocity (MNCV), sensory nerve conduction velocity (SNCV), and Toronto Clinical 
      Scoring System (TCSS) scores of the median nerve and common peroneal nerve with 
      different genotypes were compared between the 2 sets. The genotype frequencies of 
      alleles G, GG, and GC in the valid group were lower than those in the invalid 
      group; After treatment, MNCV and SNCV of CC genotype median nerve and common 
      peroneal nerve in DPN patients were higher than those before treatment; The TCSS 
      scores of the three genotypes less than post-treatment. The above results showed 
      statistically significant differences (P<0.05). Lipoic acid is influenced by the 
      miR-146a polymorphism gene in the treatment of T2DM-DPN patients, with the CC 
      genotype having a lower susceptibility and the best clinical treatment effect.
FAU - Li, Yan
AU  - Li Y
AD  - Department of Endocrinology, Tangshan Gongren Hospital, Tangshan, 063000, China. 
      liyan87073598@163.com.
FAU - Jia, Yukun
AU  - Jia Y
AD  - Department of Endocrinology, Tangshan Gongren Hospital, Tangshan, 063000, China. 
      JIAYUKUNjiayukun@163.com.
LA  - eng
PT  - Journal Article
DEP - 20231130
PL  - France
TA  - Cell Mol Biol (Noisy-le-grand)
JT  - Cellular and molecular biology (Noisy-le-Grand, France)
JID - 9216789
RN  - 0 (Antioxidants)
RN  - 0 (MicroRNAs)
RN  - 73Y7P0K73Y (Thioctic Acid)
RN  - 0 (MIRN146 microRNA, human)
SB  - IM
MH  - Humans
MH  - Antioxidants/therapeutic use
MH  - *Diabetes Mellitus, Type 2/drug therapy/genetics
MH  - *Diabetic Neuropathies/drug therapy/genetics/chemically induced
MH  - Genetic Predisposition to Disease
MH  - Genotype
MH  - *MicroRNAs/genetics
MH  - Polymorphism, Single Nucleotide/genetics
MH  - *Thioctic Acid/therapeutic use
EDAT- 2023/12/08 06:42
MHDA- 2023/12/17 13:19
CRDT- 2023/12/08 05:37
PHST- 2023/05/08 00:00 [received]
PHST- 2023/12/17 13:19 [medline]
PHST- 2023/12/08 06:42 [pubmed]
PHST- 2023/12/08 05:37 [entrez]
AID - 10.14715/cmb/2023.69.12.7 [doi]
PST - epublish
SO  - Cell Mol Biol (Noisy-le-grand). 2023 Nov 30;69(12):38-43. doi: 
      10.14715/cmb/2023.69.12.7.